Immuno - Cytokines - 3

Card Set Information

Author:
kyleannkelsey
ID:
285303
Filename:
Immuno - Cytokines - 3
Updated:
2014-10-08 21:58:50
Tags:
Immuno Cytokines
Folders:
Immuno - Cytokines - 3
Description:
Immuno - Cytokines - 3
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user kyleannkelsey on FreezingBlue Flashcards. What would you like to do?


  1. Interferon ϒ is a potent activator of_____________________.
    mononuclear phagocytes
  2. Interferon gamma increases MHC class _________ expression.
    I and II
  3. Interferon gamma acts directly on ____ and _____ lymphocytes to promote their differentiation
    T and B
  4. _____________ activates neutrophils, upregulating their respiratory burst.
    Interferon gamma
  5. Interferon gamma stimulates the _____________ activity of NK cells.
    Cytolytic
  6. IFN-γ is an activator of________________, promoting CD4+ T lymphocyte adhesion and morphological alterations that facilitate______________.
    • vascular endothelial cells
    • lymphocyte extravasation
  7. Interleukin -5 is produced predominantly by ______ cells.
    TH2
  8. IL-5 is activated by ________.
    Mast cells
  9. The major action of IL-5 is to:
    Stimulate the growth and differentiation of eosinophils.
  10. Eosinophils play a seminal role in the pathogenesis of allergic disease and asthma and are stimulated by:
    IL-5
  11. _______ activates mature eosinophils in such a way that they can kill helminths.
    IL-5
  12. High levels of IL-5 are found in:
    • Patients with:
    • Food and drug allergies,
    • Atopic dermatitis
    • Aspirin sensitivity
    • Allergic or non-allergic respiratory diseases
  13. Interleukin-12 is produced by activated_______ and __________.
    monocytes and B cells
  14. _______ is the most potent NK cell stimulator known.
    IL-12
  15. ________ stimulates the differentiation of naive CD4+ T cells to the TH1 subset.
    IL-12
  16. Colony Stimulating Factors are _________________
    A family of glycoproteins
  17. ______________ support hematopoietic colony formation.
    Colony Stimulating Factors
  18. ___________________ support the survival, proliferation and maturation of hematopoietic progenitor cells and modulate the function of____________________.
    • Colony Stimulating Factors
    • mature effector cells
  19. ________________ prevents chemotherapy-induced neutropenia.
    Colony Stimulating Factors
  20. ___________________ stimulates haemopoiesis in marrow failure.
    Colony Stimulating Factors
  21. _________________ assists in marrow transplantation.
    Colony Stimulating Factors
  22. _________________ augments effector cell function and stimulates monocyte's anticancer effects.
    Colony Stimulating Factors
  23. Granulocyte-CSF is secreted by_____________, ______________ and ___________________.
    macrophages, endothelium and leukocytes
  24. Granulocyte-CSF stimulates bone marrow to produce _______________and then direct their migration to the peripheral blood.
    Neutrophils
  25. _______________ is a growth factor for the proliferation, differentiation, effector function and survival of neutrophils.
    Granulocyte-CSF
  26. ______________ causes proliferation of endothelial cells and enhances phagocytic activity of neutrophils.
    Granulocyte-CSF
  27. ________________ results in reactive oxygen intermediate production my neutrophils.
    Granulocyte-CSF
  28. Granulocyte-CSF causes _____________________ -dependent cellular toxicity by neutrophils.
    antibody-dependent
  29. Filgrastim is __________ produced by recombinant DNA technology.
    G-CSF
  30. Filgastim is administered to patients receiving _____________________for advanced cancer.
    cytotoxic chemotherapy
  31. Filgrastim causes a dose-dependent amelioration of _______________ associated with cancer-chemotherapy.
    Neutropenia
  32. _________________ has been well tolerated and may reduce the morbidity and mortality rate associated with chemotherapy.
    Filgrastim
  33. ______________ permits the use of high doses of cytotoxic agents and a greater anti-tumor response.
    Filgrastim
  34. GM-CSF is produced by____________________________________________________.
    macrophages, T cells, mast cells, fibroblasts, and endothelial cells
  35. GM-CSF stimulates stem cells to produce__________________ and _________________.
    neutrophils and monocytes
  36. Monocytes migrate into tissues and differentiate into___________________.
    macrophages
  37. Sargramostim is a human recombinant______________.
    GM-CSF
  38. Sargramostim has beneficial effects on _________________in patients receiving high dose chemotherapy when receiving ____________________________or in advanced cancers.
    • bone marrow function
    • autologous bone marrow transplantation
  39. _______________________ has also been used in AIDS, myelodysplastic syndrome, and aplastic anemia in an attempt to stimulate bone marrow function.
    Sargramostim
  40. High doses of __________________ have produced marked weight gain, generalized edema and hypotension.
    Sargramostim
  41. ________________ also causes a dose dependent, asymptomatic eosinophilia.
    GM-CSF (Sagramostim)
  42. Interleukin 11 is produced by_________________.
    bone marrow stroma
  43. _____________ activates B cells, plasmacytomas, hepatocytes and megakaryocytes.
    IL-11
  44. ______________ plays a role in bone cell proliferation, increases platelet levels after chemotherapy.
    IL-11
  45. IL-11 also modulates ___________________responses.
    antigen-antibody
  46. _________________ promotes differentiation of progenitor B cells and megakaryocytes.
    IL-11
  47. What is the brand name for Oprelvekin?
    Neumega
  48. ___________________ is recombinant human IL-11.
    Oprelvekin (Neumega)
  49. Oprelvekin (Neumega) is used to stimulate ______________________________in patients undergoing chemotherapy.
    bone marrow to induce platelet production
  50. bone marrow to induce platelet production is administered by___________________, usually ____________ hours after chemotherapy.
    • subcutaneous injection
    • 6-24
  51. Oprelvekin (Neumega) has a half life of about _______ hours.
    7
  52. The common side effects of Oprelvekin (Neumega) include:
    Fluid retention, tachycardia, edema, nausea, vomiting and shortness of breath

What would you like to do?

Home > Flashcards > Print Preview